Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Arévalo, Estefanía ^a   Castañón, Eduardo ^a   López, Inés ^b   Salgado, Josefa ^a   Collado, Víctor ^b   Santisteban, Marta ^a   Rodríguez Ruiz, María ^a   Martín, Patricia ^a   Zubiri, Leire ^a   Patiño García, Ana ^a   Rolfo, Christian ^c   Gil Bazo, Ignacio ^a,b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Epidermal growth factor receptor; Non small cell lung cancer; Polymorphisms; Predictive factors; Prognostic factors; Thymidylate synthase

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; PEMETREXED; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE; PRIMER DNA;

5' UNTRANSLATED REGION; ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; ASTHENIA; CANCER PROGNOSIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG SAFETY; DYSPNEA; FEMALE; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MIDDLE AGED; NEUTROPENIA; OVERALL SURVIVAL; POPULATION RESEARCH; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; VARIABLE NUMBER OF TANDEM REPEAT; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CAUCASIAN; GENETIC POLYMORPHISM; GENETICS; LUNG NEOPLASMS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; DNA PRIMERS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; THYMIDYLATE SYNTHASE;

EID: 84899492119     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-98     Document Type: Article

References (24)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138, 22237781.
2. Sánchez MJ, Payer T, de Angelis R, Larrañaga N, Capocaccia R, Martinez C, CIBERESP Working Group Cancer incidence and mortality in Spain: estimates and projections for the period 1981-2012. Ann Oncol 2010, 21(Suppl 3):iii30-iii36. CIBERESP Working Group.
3. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001, 18:1059-1068. 10.1183/09031936.01.00275301, 11829087.
4. Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK. Lung cancer disease site group of cancer care Ontario's program in evidence-based care. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 2010, 5:260-274. 10.1097/JTO.0b013e3181c6f035, 20101151.
5. Cohen MH, Johnson JR, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 2005, 10:363-368. 10.1634/theoncologist.10-6-363, 15967829.
6. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551. 10.1200/JCO.2007.15.0375, 18506025.
7. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597. 10.1200/JCO.2004.08.163, 15117980.
8. Cohen MH, Cortazar P, Justice R, Pazdur R. Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC). Oncologist 2010, 15:1352-1358. 10.1634/theoncologist.2010-0224, 3227931, 21148615.
9. Lecomte T, Ferraz JM, Zinzindohoué F, Loriot MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R, Beaune P, Laurent-Puig P. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004, 10:5880-5888. 10.1158/1078-0432.CCR-04-0169, 15355920.
10. Vignoli M, Nobili S, Napoli C, Putignano AL, Morganti M, Papi L, Valanzano R, Cianchi F, Tonelli F, Mazzei T, Mini E, Genuardi M. Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. Pharmacol Res 2011, 64:242-248. 10.1016/j.phrs.2011.04.006, 21536130.
11. Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, Lorenzi E, De Vincenzo F, Simonelli M, Perrino M, Bruzzone A, Thunnissen E, Tunesi G, Giordano L, Roncalli M, Peters GJ, Santoro A. Thymidylate synthase and excision repair-cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed-carboplatin. Clin Cancer Res 2011, 17:2581-2590. 10.1158/1078-0432.CCR-10-2873, 21262916.
12. Tanaka F, Wada H, Fukui Y, Fukushima M. Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. Ann Oncol 2011, 22:1791-1797. 10.1093/annonc/mdq730, 21321092.
13. Bosch-Barrera J, Gaztañaga M, Ceballos J, Pérez-Gracia JL, López-Picazo JM, García-Foncillas J, Ferrer M, Sanz ML, Pretel M, Idoate MA, Gil-Bazo I. Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer. Onkologie 2009, 32:580-584. 10.1159/000232315, 19816075.
14. Bosch-Barrera J, Montero A, López-Picazo JM, García-Foncillas J, Ferrer M, Yuste JR, Gil-Bazo I. Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer. Lung Cancer 2009, 64:124-126. 10.1016/j.lungcan.2008.09.013, 19008012.
15. Michels J, Spano JP, Brocheriou I, Deray G, Khayat D, Izzedine H. Acute tubular necrosis and interstitial nephritis during Pemetrexed therapy. Case Rep Oncol 2009, 2:53-56. 10.1159/000208377, 2918829, 20740145.
16. Lurje G, Manegold PC, Ning Y, Pohl A, Zhang W, Lenz HJ. Thymidylate synthase gene variations: predictive and prognostic markers. Mol Cancer Ther 2009, 8:1000-1007.
17. Salgado J, Zabalegui N, Gil C, Monreal I, Rodríguez J, García-Foncillas J. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncol Rep 2007, 17:325-328.
18. Bosch-Barrera J, García-Franco C, Guillén-Grima F, Moreno-Jiménez M, López-Picazo JM, Gúrpide A, Pérez-Gracia JL, Aristu J, Torre W, García-Foncillas J, Gil-Bazo I. The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience. Clin Transl Oncol 2012, 14:835-841. 10.1007/s12094-012-0874-3, 22855163.
19. Takezawa K, Okamoto I, Okamoto W, Takeda M, Sakai K, Tsukioka S, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 2011, 104:1594-1601. 10.1038/bjc.2011.129, 3101907, 21487406.
20. Shintani Y, Ohta M, Hirabayashi H, Tanaka H, Iuchi K, Nakagawa K, Maeda H, Kido T, Miyoshi S, Matsuda H. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 2003, 104:790-795. 10.1002/ijc.11014, 12640689.
21. Hu Q, Li X, Su C, Chen X, Gao G, Zhang J, Zhao Y, Li J, Zhou C. Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer. Exp Ther Med 2012, 4:1010-1016. 3494125, 23226765.
22. Shi Q, Zhang Z, Neumann AS, Li G, Spitz MR, Wei Q. Case-control analysis of thymidylate synthase polymorphisms and risk of lung cancer. Carcinogenesis 2005, 26:649-656.
23. Wang X, Wang Y, Wang Y, Cheng J, Wang Y, Ha M. Association of thymidylate synthase gene 3′-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC. J Biomed Sci 2013, 20:5. 10.1186/1423-0127-20-5, 3577430, 23350714.
24. Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G, Peters GJ. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 2008, 73:1290-1300. 10.1124/mol.107.042382, 18187583.